{
    "hands_on_practices": [
        {
            "introduction": "In modern pathology, interpreting a test result goes beyond a simple \"positive\" or \"negative.\" We must understand the statistical power and limitations of our diagnostic tools. This first exercise provides a practical application of biostatistics to neuropathology, guiding you to calculate the Positive Predictive Value (PPV) of a common immunohistochemical screen for oligodendroglioma. Mastering this skill is crucial for understanding how pre-test probability, sensitivity, and specificity combine to determine the true meaning of a positive result in a given patient population .",
            "id": "4415849",
            "problem": "A neuropathology laboratory evaluates adult diffuse gliomas under the World Health Organization (WHO) classification, where oligodendroglioma requires an isocitrate dehydrogenase 1 (IDH1) mutation and whole-arm codeletion of chromosome arms $1p/19q$ by integrated histologic and molecular methods. As part of screening, the laboratory uses IDH1 R132H immunohistochemistry, which detects the canonical IDH1 R132H mutant protein. In a cohort where the pretest prevalence of oligodendroglioma among all primary infiltrating gliomas is $0.30$, validation against the integrated diagnosis shows that the IDH1 R132H immunostain has sensitivity $0.92$ for oligodendroglioma and specificity $0.70$ for non-oligodendroglioma entities (for example, astrocytoma or other gliomas).\n\nUsing only fundamental definitions from diagnostic test evaluation and probability, compute the positive predictive value (PPV) of a positive IDH1 R132H immunostain for oligodendroglioma in this cohort. Express your final answer as a decimal and round to four significant figures.",
            "solution": "The problem statement is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- The pretest prevalence of oligodendroglioma among all primary infiltrating gliomas is $0.30$.\n- The test is IDH1 R132H immunohistochemistry.\n- The condition being tested for is oligodendroglioma, as defined by the WHO classification (IDH1 mutation and whole-arm codeletion of chromosome arms $1p/19q$).\n- The sensitivity of the test for oligodendroglioma is $0.92$.\n- The specificity of the test for non-oligodendroglioma entities is $0.70$.\n- The task is to compute the positive predictive value (PPV) of a positive IDH1 R132H immunostain for oligodendroglioma.\n- The final answer must be a decimal rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded:** The problem is based on established principles of neuropathology and diagnostic test evaluation. The WHO classification of gliomas, the role of IDH1 mutations and $1p/19q$ codeletion in defining oligodendroglioma, and the use of immunohistochemistry as a screening tool are all scientifically sound. The provided values for prevalence, sensitivity, and specificity are realistic for a diagnostic marker.\n- **Well-Posed:** The problem provides all necessary information to calculate the positive predictive value. The definitions of prevalence, sensitivity, and specificity are standard in biostatistics and epidemiology, leading to a unique, meaningful solution for the PPV.\n- **Objective:** The problem is stated using precise, quantitative, and unbiased language. There are no subjective or opinion-based statements.\n\nThe problem does not exhibit any of the flaws that would render it invalid. It is scientifically sound, well-posed, objective, and complete.\n\n### Step 3: Verdict and Action\nThe problem is valid. A formal solution will be provided.\n\n### Solution\nThe objective is to calculate the Positive Predictive Value (PPV) of a diagnostic test. The PPV is the probability that a subject has the disease given a positive test result. We will use the fundamental definitions of conditional probability and Bayes' theorem.\n\nLet $D$ be the event that a patient has an oligodendroglioma.\nLet $D^c$ be the event that a patient has a non-oligodendroglioma entity (the complement of $D$).\nLet $T^+$ be the event of a positive IDH1 R132H immunostain.\nLet $T^-$ be the event of a negative IDH1 R132H immunostain.\n\nFrom the problem statement, we are given the following probabilities:\n- The pretest prevalence of the disease: $P(D) = 0.30$.\n- The probability of a non-oligodendroglioma entity is the complement of the prevalence: $P(D^c) = 1 - P(D) = 1 - 0.30 = 0.70$.\n- The sensitivity of the test, which is the probability of a positive test given the presence of the disease: $P(T^+|D) = 0.92$.\n- The specificity of the test, which is the probability of a negative test given the absence of the disease: $P(T^-|D^c) = 0.70$.\n\nWe need to compute the PPV, which is the conditional probability $P(D|T^+)$. According to Bayes' theorem, this is given by:\n$$\nP(D|T^+) = \\frac{P(T^+|D)P(D)}{P(T^+)}\n$$\nTo use this formula, we must first calculate $P(T^+)$, the total probability of a positive test result. This can be found using the law of total probability:\n$$\nP(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)\n$$\nWe have $P(T^+|D)$, $P(D)$, and $P(D^c)$. We need to determine $P(T^+|D^c)$, which is the probability of a positive test given the absence of the disease. This is also known as the false positive rate. It is the complement of the specificity:\n$$\nP(T^+|D^c) = 1 - P(T^-|D^c) = 1 - 0.70 = 0.30\n$$\nNow, we can substitute the known values into the equation for $P(T^+)$:\n$$\nP(T^+) = (0.92)(0.30) + (0.30)(0.70)\n$$\n$$\nP(T^+) = 0.276 + 0.210 = 0.486\n$$\nThe total probability of obtaining a positive test is $0.486$.\n\nFinally, we can calculate the PPV, $P(D|T^+)$, by substituting the values into the Bayes' theorem formula:\n$$\nP(D|T^+) = \\frac{P(T^+|D)P(D)}{P(T^+)} = \\frac{(0.92)(0.30)}{0.486}\n$$\n$$\nP(D|T^+) = \\frac{0.276}{0.486}\n$$\nPerforming the division:\n$$\nP(D|T^+) \\approx 0.56790123...\n$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\nP(D|T^+) \\approx 0.5679\n$$\nThis is the positive predictive value of the IDH1 R132H immunostain for oligodendroglioma in this specific cohort.",
            "answer": "$$\\boxed{0.5679}$$"
        },
        {
            "introduction": "The classification of oligodendroglioma is not merely an academic exercise; it has profound implications for treatment and prognosis. Molecular markers, such as the $1p/19q$ codeletion, stratify patients into distinct groups with different responses to therapy. This practice delves into the fundamentals of survival analysis, asking you to quantify the overall benefit of a chemotherapy regimen in a mixed population. By working through this hypothetical scenario, you will develop an intuition for how hazard ratios in molecularly defined subgroups contribute to the overall treatment effect observed in a clinical trial .",
            "id": "4415854",
            "problem": "A neuropathology research team is evaluating treatment effects in diffuse gliomas with oligodendroglial lineage. They are particularly interested in oligodendrogliomas stratified by combined whole-arm deletions of chromosome arms 1p and 19q (codeletion). Procarbazine, Lomustine (also known as CCNU), and Vincristine (PCV) is added to radiotherapy in the experimental arm. Using survival analysis, they model hazards as approximately constant over the time window of interest and use relative risks (hazard ratios) reported for each molecular subgroup to estimate the effect of combined therapy on the overall cohort.\n\nAssume the following, all referenced to all-cause mortality within a fixed time window:\n- The proportion of patients with 1p/19q codeletion is $p = 0.40$, and the proportion without codeletion is $1 - p = 0.60$.\n- Under radiotherapy alone, the instantaneous mortality hazards (per year) are $h_{\\mathrm{C},0} = 0.06$ for the codeleted subgroup and $h_{\\mathrm{N},0} = 0.12$ for the non-codeleted subgroup.\n- The hazard ratios for combined radiotherapy plus PCV versus radiotherapy alone are $r_{\\mathrm{C}} = 0.59$ in the codeleted subgroup and $r_{\\mathrm{N}} = 0.85$ in the non-codeleted subgroup.\n\nUsing only foundational definitions from survival analysis (hazard, hazard ratio, and mixture of subgroup hazards), derive from first principles and then calculate the expected overall reduction in hazard in the combined-therapy arm relative to radiotherapy alone for the entire cohort. Express the final result as a decimal fraction (unitless) and round your answer to four significant figures.",
            "solution": "The user has submitted a problem for validation and solution.\n\n### Step 1: Extract Givens\n- Proportion of patients with 1p/19q codeletion: $p = 0.40$\n- Proportion of patients without 1p/19q codeletion: $1 - p = 0.60$\n- Instantaneous mortality hazard (per year) under radiotherapy alone for the codeleted subgroup: $h_{\\mathrm{C},0} = 0.06$\n- Instantaneous mortality hazard (per year) under radiotherapy alone for the non-codeleted subgroup: $h_{\\mathrm{N},0} = 0.12$\n- Hazard ratio for combined therapy vs. radiotherapy alone in the codeleted subgroup: $r_{\\mathrm{C}} = 0.59$\n- Hazard ratio for combined therapy vs. radiotherapy alone in the non-codeleted subgroup: $r_{\\mathrm{N}} = 0.85$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the validation criteria.\n- **Scientifically Grounded**: The problem is set in the context of neuro-oncology, specifically concerning oligodendrogliomas, the 1p/19q codeletion prognostic marker, and the PCV chemotherapy regimen. These are well-established concepts in pathology and clinical oncology. The use of survival analysis concepts like hazard rates and hazard ratios is the standard methodology for evaluating treatment efficacy in clinical trials. The provided numerical values are plausible. The problem is scientifically grounded.\n- **Well-Posed**: The problem provides all necessary data to calculate a specific, well-defined quantity (overall relative hazard reduction). The assumption of \"approximately constant\" hazards simplifies the model appropriately for a solvable problem. A unique and meaningful solution exists. The problem is well-posed.\n- **Objective**: The problem statement is formulated with precise, quantitative, and unbiased language. All terms are clearly defined or are standard in the field of biostatistics. The problem is objective.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\n### Solution Derivation\nThe objective is to determine the overall reduction in hazard in the combined-therapy arm relative to the radiotherapy-alone arm for the entire cohort. This relative reduction is given by the expression $\\frac{H_0 - H_1}{H_0} = 1 - \\frac{H_1}{H_0}$, where $H_0$ is the overall hazard rate for the cohort under radiotherapy alone, and $H_1$ is the overall hazard rate under combined therapy.\n\nA key principle of survival analysis in heterogeneous populations is that the overall hazard rate is a weighted average of the hazard rates of its constituent subgroups. The weight for each subgroup is its proportion within the population currently at risk (i.e., those who have not yet experienced the event).\n\nLet $S_C(t)$ and $S_N(t)$ be the survival functions for the codeleted (C) and non-codeleted (N) subgroups, respectively. The overall survival function for the cohort is a mixture model:\n$$S(t) = p S_C(t) + (1-p) S_N(t)$$\nThe overall hazard function $H(t)$ is defined as $H(t) = -\\frac{S'(t)}{S(t)}$. Using the product rule and the definition of subgroup hazards, $h_i(t) = -S'_i(t)/S_i(t)$, we can derive the expression for the overall hazard:\n$$H(t) = \\frac{p \\cdot h_C(t) S_C(t) + (1-p) \\cdot h_N(t) S_N(t)}{p S_C(t) + (1-p) S_N(t)}$$\nThis expression shows that the overall hazard $H(t)$ is time-dependent, because the relative proportions of the subgroups C and N among the survivors change over time (due to their different hazard rates).\n\nThe problem asks for a single value representing the overall hazard reduction. The most direct and standard approach, consistent with deriving from first principles, is to evaluate the hazard at the beginning of the study, at time $t=0$. At this point, the composition of the cohort is exactly known (proportions $p$ and $1-p$), as no subjects have yet been lost. At $t=0$, the survival functions are unity for all subgroups, i.e., $S_C(0) = 1$ and $S_N(0) = 1$.\n\nThe overall hazard for the radiotherapy-alone arm (Arm 0) at $t=0$ is:\n$$H_0(0) = \\frac{p \\cdot h_{C,0} S_C(0) + (1-p) \\cdot h_{N,0} S_N(0)}{p S_C(0) + (1-p) S_N(0)} = p \\cdot h_{C,0} + (1-p) \\cdot h_{N,0}$$\n\nFor the combined-therapy arm (Arm 1), the hazards for the subgroups are given by the hazard ratios:\n$$h_{C,1} = r_C \\cdot h_{C,0}$$\n$$h_{N,1} = r_N \\cdot h_{N,0}$$\nThe overall hazard for the combined-therapy arm at $t=0$ is therefore:\n$$H_1(0) = p \\cdot h_{C,1} + (1-p) \\cdot h_{N,1} = p \\cdot (r_C h_{C,0}) + (1-p) \\cdot (r_N h_{N,0})$$\n\nThe overall hazard ratio for the cohort at $t=0$ is $R_{overall}(0) = \\frac{H_1(0)}{H_0(0)}$.\n$$R_{overall}(0) = \\frac{p \\cdot r_C \\cdot h_{C,0} + (1-p) \\cdot r_N \\cdot h_{N,0}}{p \\cdot h_{C,0} + (1-p) \\cdot h_{N,0}}$$\n\nThe desired overall relative reduction in hazard is $1 - R_{overall}(0)$.\n\nWe now substitute the given values into the expressions for $H_0(0)$ and $H_1(0)$.\nGiven: $p = 0.40$, $h_{C,0} = 0.06$, $h_{N,0} = 0.12$, $r_C = 0.59$, $r_N = 0.85$.\n\nFirst, calculate the overall baseline hazard $H_0(0)$:\n$$H_0(0) = (0.40) \\cdot (0.06) + (0.60) \\cdot (0.12) = 0.024 + 0.072 = 0.096$$\n\nNext, calculate the overall treatment hazard $H_1(0)$:\n$$H_1(0) = (0.40) \\cdot (0.59) \\cdot (0.06) + (0.60) \\cdot (0.85) \\cdot (0.12)$$\n$$H_1(0) = (0.40) \\cdot (0.0354) + (0.60) \\cdot (0.102)$$\n$$H_1(0) = 0.01416 + 0.0612 = 0.07536$$\n\nThe overall hazard ratio at $t=0$ is:\n$$R_{overall}(0) = \\frac{H_1(0)}{H_0(0)} = \\frac{0.07536}{0.096} = 0.785$$\n\nFinally, the overall relative reduction in hazard is:\n$$\\text{Relative Reduction} = 1 - R_{overall}(0) = 1 - 0.785 = 0.215$$\n\nThe problem requires the answer to be rounded to four significant figures. The exact result is $0.215$. To express this with four significant figures, we append a trailing zero.\n$$\\text{Relative Reduction} \\approx 0.2150$$",
            "answer": "$$\n\\boxed{0.2150}\n$$"
        },
        {
            "introduction": "The pinnacle of modern diagnostic pathology is the \"integrated diagnosis,\" a process that requires synthesizing evidence from morphology, protein expression, and genomic analysis. This final practice presents a realistic and complex case where different tests yield apparently discordant results. To solve this puzzle, you must apply foundational principles of molecular biology and understand the specific strengths and limitations of each assay. This exercise challenges you to think like a molecular neuropathologist, prioritizing evidence to resolve ambiguity and arrive at a definitive diagnosis according to the latest World Health Organization (WHO) criteria .",
            "id": "4415916",
            "problem": "A stereotactic biopsy from a frontal lobe mass in a $45$-year-old adult shows classic oligodendroglial cytology with perinuclear clearing and delicate branching capillaries. In a laboratory with validated protocols, the following results are obtained on the tumor-rich block (estimated tumor cell content $\\approx 30\\%$ by manual count): immunohistochemistry (IHC) for the mutant-specific Isocitrate Dehydrogenase 1 (IDH1) R132H antibody is negative; Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) nuclear expression is retained; tumor suppressor protein p53 shows only scattered positive nuclei; a genome-wide single nucleotide polymorphism (SNP) array demonstrates whole-arm $1p/19q$ codeletion; targeted next-generation sequencing (NGS) detects an IDH2 R172K variant at a variant allele fraction (VAF) of $10\\%$ with a mean amplicon depth of $1000\\times$, and no other IDH1/2 variants. Internal positive and negative controls for IHC are appropriate, and external run controls meet performance specifications.\n\nUsing fundamental principles that link genotype to protein phenotype (deoxyribonucleic acid to ribonucleic acid to protein), and considering the analytical performance characteristics of IHC versus DNA sequencing, propose criteria to resolve the discrepancy between the negative IDH1 R132H IHC and the positive IDH2 sequencing result, and prioritize which evidence should be considered the most reliable for the integrated diagnosis under The World Health Organization (WHO) 2021/2024 classification.\n\nWhich option best states a principled, stepwise approach and the correct prioritization of evidence in this discordant scenario?\n\nA. Because IDH1 R132H IHC is negative, classify the tumor as IDH-wildtype; disregard sequencing as likely contamination and ignore copy-number results, since IHC directly reflects protein and is therefore the gold standard.\n\nB. Accept oligodendroglioma based solely on the $1p/19q$ codeletion; IDH status is unnecessary when whole-arm $1p/19q$ codeletion is present, so no further testing or reconciliation is required.\n\nC. Prioritize high-quality sequencing that identifies a known pathogenic noncanonical IDH1/2 variant with sufficient read depth and a VAF compatible with tumor purity; treat a negative IDH1 R132H IHC as expected for noncanonical IDH variants; confirm lineage with whole-arm $1p/19q$ codeletion by a genome-wide method; optionally repeat IHC or use broader mutant-specific antibodies as a secondary check, then render an integrated diagnosis of IDH-mutant, $1p/19q$-codeleted oligodendroglioma.\n\nD. Consider both IHC and sequencing unreliable in small biopsies; rely on histology alone to diagnose oligodendroglioma, because morphology is the most stable feature across assays.",
            "solution": "The problem statement presents a case of a frontal lobe tumor in a $45$-year-old adult with a set of histological, immunohistochemical (IHC), and molecular genetic findings. The task is to resolve an apparent discrepancy between a negative IHC result for the most common Isocitrate Dehydrogenase (IDH) mutation and a positive sequencing result for a less common IDH mutation, and to determine the correct diagnostic interpretation based on the World Health Organization (WHO) classification of Central Nervous System (CNS) tumors.\n\n### Step 1: Extraction of Givens\n- **Patient and Tumor**: $45$-year-old adult, frontal lobe mass.\n- **Histology**: Classic oligodendroglial cytology (perinuclear clearing, delicate branching capillaries).\n- **Tumor Content**: Estimated $\\approx 30\\%$ tumor cells in the analyzed sample.\n- **IHC for IDH1 R132H**: Negative.\n- **IHC for ATRX**: Retained nuclear expression.\n- **IHC for p53**: Scattered positive nuclei (wild-type pattern).\n- **Copy Number Analysis**: Whole-arm $1p/19q$ codeletion detected by a genome-wide single nucleotide polymorphism (SNP) array.\n- **Sequencing Analysis**: Targeted next-generation sequencing (NGS) detects an IDH2 R172K variant. The variant allele fraction (VAF) is $10\\%$. The mean amplicon depth is $1000\\times$. No other IDH1/2 variants were detected.\n- **Quality Control**: All laboratory quality control measures were met.\n\n### Step 2: Validation of the Problem Statement\nThe problem is scientifically grounded, well-posed, and objective. It describes a realistic clinical scenario in neuropathology, requiring the integration of multiple data types (histology, IHC, DNA copy number, and DNA sequencing) to arrive at a diagnosis according to the current WHO classification. The core issue is an apparent discordance between two tests for IDH mutation status, which is a common diagnostic challenge. The data provided are internally consistent and sufficient for a rigorous analysis.\n\n1.  **Scientific Grounding**: The problem is based on established principles of molecular pathology and neuro-oncology. The central dogma of molecular biology (DNA $\\rightarrow$ RNA $\\rightarrow$ protein) is fundamental to understanding the relationship between the genotype (assessed by NGS and SNP array) and the phenotype (assessed by IHC). The specific markers (IDH1/2 mutations, $1p/19q$ codeletion, ATRX, p53) are the defining and characteristic molecular alterations for diffuse gliomas in the WHO 2021 classification.\n2.  **Internal Consistency**: The provided data are not contradictory when interpreted correctly.\n    - The negative IHC for IDH1 R132H only rules out the presence of the specific p.Arg132His mutant protein. It gives no information about other possible mutations in the IDH1 gene or any mutations in the IDH2 gene.\n    - The NGS result shows an IDH2 R172K mutation. This is a known, albeit less common, pathogenic mutation found in gliomas. Therefore, a negative result with the highly specific IDH1 R132H antibody is an **expected finding** in a tumor with an IDH2 mutation.\n    - The quantitative NGS data are robust. A mean read depth of $1000\\times$ provides high confidence in variant calling. The observed VAF of $10\\%$ is consistent with the estimated tumor purity of $\\approx 30\\%$. For a heterozygous mutation in a diploid genome, the expected VAF is half the tumor purity, i.e., $0.5 \\times 30\\% = 15\\%$. A measured value of $10\\%$ is well within the plausible range, accounting for potential inaccuracies in manual cell counting and sampling effects.\n3.  **Well-Posed Nature**: The problem is well-posed as it provides all necessary information to apply the WHO diagnostic criteria and arrive at a single, correct integrated diagnosis.\n\n### Verdict on Validity\nThe problem statement is **valid**.\n\n### Derivation of the Correct Diagnostic Approach\n\nThe WHO 2021 classification of CNS tumors defines an **Oligodendroglioma, IDH-mutant, and $1p/19q$-codeleted** by the combined presence of two molecular criteria:\n1.  An IDH1 or IDH2 gene mutation.\n2.  Whole-arm $1p/19q$ codeletion.\n\nWe must evaluate the provided evidence against these definitional criteria.\n\n1.  **Evaluation of IDH Status**: The IHC screen for the IDH1 R132H mutation is negative. This antibody is extremely specific and does not react with wild-type IDH1 protein or with other mutant IDH1 or IDH2 proteins. Therefore, this result simply indicates the tumor does not harbor the single most common IDH mutation ($\\approx 90\\%$ of all IDH mutations in glioma). However, the targeted NGS analysis, a more comprehensive method, definitively identifies a pathogenic IDH2 R172K mutation. The high read depth ($1000\\times$) and compatible VAF ($10\\%$) confirm this is a true positive result originating from the tumor cells, not an artifact or contamination. Therefore, the tumor is unequivocally **IDH-mutant**. The correct principle is to prioritize comprehensive genotypic analysis (sequencing) over a limited phenotypic screen (single-mutation IHC) when results are discordant.\n\n2.  **Evaluation of $1p/19q$ Status**: The SNP array, a genome-wide technique, demonstrates whole-arm $1p/19q$ codeletion. This is the gold-standard method for assessing this alteration. Therefore, the tumor is definitively **$1p/19q$-codeleted**.\n\n3.  **Evaluation of Supporting Evidence**:\n    - **ATRX**: Retained nuclear expression of ATRX is characteristic of oligodendrogliomas. Loss of ATRX expression is, by contrast, a defining feature of IDH-mutant astrocytomas. This finding strongly supports an oligodendroglial lineage.\n    - **p53**: A wild-type expression pattern for p53 (only scattered positive cells) is also typical for oligodendroglioma, whereas diffuse overexpression is associated with astrocytomas.\n    - **Histology**: The \"classic oligodendroglial cytology\" is suggestive and aligns with the molecular findings, but morphology alone is not sufficient for a definitive diagnosis under the modern classification.\n\n4.  **Integration for Diagnosis**: The tumor meets both essential molecular criteria for oligodendroglioma: it is IDH-mutant (specifically, IDH2-mutant via NGS) and $1p/19q$-codeleted (via SNP array). The supporting IHC for ATRX and p53, as well as the histology, are all consistent with this diagnosis.\n\n**Conclusion of Principled Approach**: The correct approach is to prioritize the results from the most comprehensive and definitive assays. In this case, the NGS data for mutation status and the SNP array data for copy number status are the primary evidence. The IHC results are interpreted in light of the sequencing data; the negative IDH1 R132H result is expected and does not contradict the IDH2-mutant status. The final diagnosis is Oligodendroglioma, IDH-mutant, and $1p/19q$-codeleted.\n\n### Evaluation of Provided Options\n\n**Option A**: \"Because IDH1 R132H IHC is negative, classify the tumor as IDH-wildtype; disregard sequencing as likely contamination and ignore copy-number results, since IHC directly reflects protein and is therefore the gold standard.\"\nThis is **Incorrect**. It demonstrates a fundamental misunderstanding of the analytical limitations of the IDH1 R132H antibody. It improperly discards high-quality, concordant sequencing data and the definitive copy number result. Citing IHC as the universal \"gold standard\" over DNA sequencing for genotype is factually wrong in the context of modern molecular diagnostics.\n\n**Option B**: \"Accept oligodendroglioma based solely on the $1p/19q$ codeletion; IDH status is unnecessary when whole-arm $1p/19q$ codeletion is present, so no further testing or reconciliation is required.\"\nThis is **Incorrect**. This contradicts the mandatory WHO 2021 diagnostic criteria, which strictly require **both** an IDH mutation **and** $1p/19q$ codeletion for the diagnosis of oligodendroglioma. The presence of $1p/19q$ codeletion without an IDH mutation would define a different, much rarer tumor entity.\n\n**Option C**: \"Prioritize high-quality sequencing that identifies a known pathogenic noncanonical IDH1/2 variant with sufficient read depth and a VAF compatible with tumor purity; treat a negative IDH1 R132H IHC as expected for noncanonical IDH variants; confirm lineage with whole-arm $1p/19q$ codeletion by a genome-wide method; optionally repeat IHC or use broader mutant-specific antibodies as a secondary check, then render an integrated diagnosis of IDH-mutant, $1p/19q$-codeleted oligodendroglioma.\"\nThis is **Correct**. This option accurately describes the correct, principled, and stepwise diagnostic process. It correctly prioritizes high-quality sequencing, correctly interprets the IHC result as an expected negative, correctly incorporates the copy number data, and arrives at the precise WHO 2021 diagnosis. It reflects expert-level reasoning in modern neuro-oncology pathology.\n\n**Option D**: \"Consider both IHC and sequencing unreliable in small biopsies; rely on histology alone to diagnose oligodendroglioma, because morphology is the most stable feature across assays.\"\nThis is **Incorrect**. This represents a regression to an outdated, pre-molecular diagnostic paradigm. The WHO classification is explicitly layered, with molecular parameters being definitive over histological features. While low tumor content can be a challenge, the provided data ($1000\\times$ depth) indicate the molecular tests were successful and reliable. Dismissing robust molecular data in favor of subjective morphology is a grave error in modern practice.",
            "answer": "$$\\boxed{C}$$"
        }
    ]
}